Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Tumour-agnostic precision therapeutics: What is the way forward? (In collaboration with National Societies)

Challenges in the development of tumour-agnostic targeted agents

Date

01 Dec 2022

Session

Tumour-agnostic precision therapeutics: What is the way forward? (In collaboration with National Societies)

Topics

Targeted Therapy;  Molecular Oncology

Tumour Site

Presenters

Kan Yonemori

Authors

K. Yonemori

Author affiliations

  • Breast And Medical Oncology, National Cancer Center - Tsukiji Campus, 104-0045 - Chuo-ku/JP

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.